Ascendis Pharma (ASND) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Product Revenue: EUR 315 million, more than doubling year-over-year.

Total Revenue: EUR 339 million, including EUR 24 million in non-product collaboration revenue.

YORVIPATH Revenue: EUR 252 million, achieving blockbuster status in the U.S. within the second year of launch.

SKYTROFA Revenue: EUR 55 million, reflecting increased demand.

YUVIWEL Revenue: EUR 8 million in its first quarter post-launch.

R&D Expenses: EUR 76 million, up from EUR 59 million in Q1.

SG&A Expenses: EUR 173 million, increased from EUR 145 million in Q1 due to commercial launch investments.

Operating Profit: EUR 220 million, with a non-IFRS operating profit of EUR 92 million and a margin of 27%.

Net Profit: EUR 207 million, with a non-IFRS net profit of EUR 61 million.

Cash Position: EUR 812 million in cash and equivalents, following a EUR 56 million share repurchase program.

2Strategic Updates and Business Highlights

Product Portfolio: Continued strong demand for TransCon products (SKYTROFA, YORVIPATH, YUVIWEL) is driving growth.

YORVIPATH: Steady uptake in the U.S. and international markets, with plans for label expansions to include patients aged 12-18 and higher doses.

YUVIWEL: Rapid uptake in the U.S. with over 220 patients enrolled and 65% approved for reimbursement. Positioned to become the leading therapy for achondroplasia.

Combination Therapies: Advancements in combination treatments involving TransCon CNP and TransCon Growth Hormone show promise for establishing new treatment standards.

Global Expansion: Ongoing efforts to expand the TransCon technology platform and establish new therapeutic areas.

3Forward Guidance and Outlook

Revenue Expectations: Anticipate continued growth for YORVIPATH and stable revenue for SKYTROFA. Encouraged by early demand trends for YUVIWEL.

Long-term Goals: Reinforced belief in achieving EUR 5 billion in revenues by 2030, with potential to exceed EUR 10 billion in the following decades.

Operating Cash Flow: Expecting to generate over EUR 500 million in cash flow from operating activities for the year.

4Bad News, Challenges, or Points of Concern

Legal Challenges: Ongoing patent litigation with BioMarin regarding YUVIWEL raises uncertainties, although management remains confident in their position.

Market Dynamics: Questions about the sustainability of patient enrollment rates for YUVIWEL, particularly during seasonal fluctuations.

Dropout Rates: Noted that most dropouts for YORVIPATH occur during the titration phase, indicating a need for enhanced patient support.

Competitive Landscape: Concerns about the competitive pressures from BioMarin and other therapies in the achondroplasia market.

5Notable Q&A Insights

Cash Flow Guidance: Management refrained from providing an upper bound on cash flow expectations, indicating strong early demand for YUVIWEL.

Market Expansion: Management believes that YUVIWEL is expanding the overall market for achondroplasia treatments, with a mix of new patients and those returning to therapy.

Legal Strategy: Management expressed confidence in their legal standing against BioMarin, emphasizing the public interest in maintaining access to YUVIWEL.

Pipeline Development: Management aims to file at least one IND or CTA yearly based on new chemical entities, with expectations for new trials to commence soon. This summary encapsulates the key points from the earnings call, providing a balanced view of Ascendis Pharma's current financial health, strategic direction, and potential risks ahead.